2G, or T415N) had been subjected to immunoblotting following CCCP remedy
2G, or T415N) have been subjected to immunoblotting following CCCP remedy, no ubiquitin-oxyester adduct was observed (Fig. 1F), indicating that the three Parkin pathogenic mutations examined compromised formation in the…